Asset Allocation & Management Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Asset Allocation & Management Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-567	Closed	-$253K	–	95
2026 Q1	$253K	Hold	567	–	–	0.09%	86
2025 Q4	$257K	Hold	567	–	–	0.1%	82
2025 Q3	$222K	Hold	567	–	–	0.09%	85
2025 Q2	$252K	Hold	567	–	–	0.12%	78
2025 Q1	$275K	Hold	567	–	–	0.14%	74
2024 Q4	$228K	Buy	+567	New	+$263K	0.12%	78

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Allocation & Management Company's VRTX Position: Q2 2026 in Review

Asset Allocation & Management Company sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 567 shares — an estimated $253K sold.

Asset Allocation & Management Company first reported a position in VRTX in Q4 2024 and held it in 6 quarters. The position peaked at $275K in Q1 2025. 734 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Asset Allocation & Management Company reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Asset Allocation & Management Company sold 567 Vertex Pharmaceuticals shares in Q2 2026, an estimated $253K.
Asset Allocation & Management Company first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Asset Allocation & Management Company's Vertex Pharmaceuticals position peaked at $275K in Q1 2025.
734 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Asset Allocation & Management Company's 13F filing for Q2 2026, filed 15 Jul 2026.